Current Document Type: JAdPrO_Article Monoclonal Antibodies in the Treatment of Multiple Myeloma - JADPRO
Prescriber's Corner

Monoclonal Antibodies in the Treatment of Multiple Myeloma

Charise Gleason,(1) MSN, NP-BC, AOCNP®, Hollie Devine,(2) MSN, ANP-BC, Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, Deborah Doss,(4) RN, OCN®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership Board

1Winship Cancer Institute of Emory University, Atlanta, Georgia; 2The Ohio State University Medical Center, Columbus, Ohio; 3Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; 4Dana-Farber Cancer Institute, Boston, Massachusetts; 5The University of Arizona Cancer Center, Tuscon, Arizona

Charise Gleason, MSN, NP-BC, AOCNP®, Winship Cancer Institute of Emory University, 1365 Clifton Road, NE, Atlanta, GA 30322. E-mail:

Authors’ disclosures of potential conflicts of interest are found at the end of this article

J Adv Pract Oncol 2016;7:53–57 | doi: 10.6004/jadpro.2016.7.2.14 | © 2016 Harborside Press®


For access to the full length article, please sign in.

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.